Ionis Reveals Encouraging Findings from Phase 3 Balance Trial of Olezarsen in Familial Chylomicronemia Syndrome
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has unveiled comprehensive findings from the Phase 3 Balance study of olezarsen, its leading independent investigational medication, targeted at adults grappling with familial chylomicronemia syndrome…
Al-Shifa Hospital Reduced to Ruins After Six Months of War, Finds WHO Mission
A joint mission led by the World Health Organization (WHO) and several other agencies visited Al-Shifa Hospital in north Gaza on April 5 to assess the damage caused by the…
Teva’s Latest Pharmacokinetic Modeling Data Shows UZEDY® Benefits for Schizophrenia Patients at SIRS 2024
Teva Pharmaceuticals Unveils Promising PK Modeling Data and Clinical Insights at SIRS 2024 At the Schizophrenia International Research Society (SIRS) 2024 Congress, Teva Pharmaceuticals, a leading U.S. affiliate of Teva…
Positive Findings: Zilebesiran Combined with Antihypertensives for Uncontrolled Hypertension
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) has unveiled promising outcomes from the KARDIA-2 Phase 2 investigation, evaluating the effectiveness and safety of zilebesiran when combined with one of three standard antihypertensive…
Study: mRNA Immunotherapy Shows Long-Term Immune Response and Delayed Tumor Return in Pancreatic Cancer Patients
BioNTech SE (Nasdaq: BNTX) has released promising findings from a Phase 1 trial involving the mRNA-based individualized neoantigen-specific immunotherapy (iNeST) candidate autogene cevumeran (also known as BNT122, RO7198457) for patients…
ICON Announces CFO Transition
ICON, a globally renowned healthcare intelligence and clinical research organization, has announced that its Chief Financial Officer, Brendan Brennan, will be stepping down from his position in the fourth quarter…
Novartis to Seek Pre-Taxane Label Expansion for Pluvicto® in Second Half of 2024 Following Latest Data from Phase III PSMAfore Trial
Updated findings on overall survival (OS) from a planned evaluation, encompassing around 75% of data, reveal an OS hazard ratio below 1.0 (HR<1.0) within the intent-to-treat (ITT) population, not adjusted…
Imfinzi Boosts Survival in Limited-Stage Small Cell Lung Cancer: ADRIATIC Trial Results
AstraZeneca’s Imfinzi Shows Significant Improvement in Survival Rates for Limited-Stage Small Cell Lung Cancer Patients A recent Phase III trial, ADRIATIC, revealed promising outcomes for AstraZeneca’s Imfinzi (durvalumab) in treating…
Phase 3 Trial: Merck’s MK-1084 Oral KRAS G12C Inhibitor with KEYTRUDA® for Metastatic Non-Small Cell Lung Cancer
Merck, known as MSD outside of the United States and Canada, has announced the commencement of a Phase 3 clinical trial to evaluate MK-1084, an investigational oral selective KRAS G12C…
Bristol Myers Squibb Unveils 2023 Environmental, Social, and Governance Report: Highlighting Advancements and Establishing Future Objectives
Bristol Myers Squibb (NYSE: BMY) has unveiled its 2023 Environmental, Social, and Governance (ESG) Report, spotlighting significant progress, a refined strategy, and ambitious goals in its ESG initiatives. Rooted in…
EU Widens Approval for Bristol Myers Squibb’s Reblozyl® for First-Line LR-MDS Anemia
Bristol Myers Squibb (NYSE: BMY) has disclosed that the European Commission (EC) has broadened the approval of Reblozyl® (luspatercept) to encompass the initial treatment of adult patients grappling with transfusion-dependent…
US Accepts Biologics License Application for Datopotamab Deruxtecan in Advanced HR-Positive, HER2-Negative Breast Cancer Post-Prior Treatment
AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been officially accepted in the United States. This application targets the treatment of adult patients grappling with…